Biotech Pinpoints Third Set of Targets for Potential Alzheimers Treatment [ARFXF, PMN]

With this achievement, the firm expands its potential partnering opportunities.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) identified novel targets on misfolded, pathological forms of tau, which have been implicated in neuronal dysfunction “seen in Alzheimer’s disease, frontotemporal dementia and other tauopathies such as repetitive head injury (chronic traumatic encephalopathy, or CTE),” the company announced.

This new development is significant for ProMIS as it now intends to create antibody therapies to selectively block these newly identified toxic forms of tau, to potentially treat Alzheimer’s disease and other neurodegenerative diseases.

A therapeutic to target toxic tau, yet to be developed, and ProMIS’ existing therapeutic to target toxic oligomers of amyloid beta, PMN310, could potentially be used together to treat Alzheimer’s disease in a “one-two punch” format, the company indicated.

“Having previously announced encouraging antibody candidates for amyotrophic lateral sclerosis (targeting TDP43) and Parkinson’s disease (targeting alpha-synuclein) and now novel targets on tau protein, we have additional exciting opportunities for high-value pharma partnering across a broad spectrum of neurodegenerative diseases in 2019,” said ProMIS President and CEO Dr. Elliot Goldstein.

[NLINSERT]

Disclosure:

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

*